Dr. Rasha Al-Lamee is an Interventional Cardiology Consultant at Imperial College Healthcare NHS Trust and a clinical academic at Imperial College London. She has expertise in general and interventional cardiology. She is a clinical trialist and her research interests are in coronary intervention, invasive coronary physiology and invasive intravascular imaging. Dr. Al-Lamee is known throughout the world for her academic in cardiovascular research with a focus on clinical trials that impact the care of patients with coronary artery disease. She believes in the rigorous testing of clinical practice and the use of evidence-based medicine in all aspects of medical care. She designed, conducted and led the ORBITA trial. This was the first randomised placebo-controlled trial of coronary angioplasty and is one of the most widely cited clinical trials in cardiology of the decade. ORBITA investigated the use of coronary angioplasty in treating single vessel stable coronary artery disease. She is lead author of the primary publication in The Lancet and the two secondary publications both published in Circulation. She is the NIHR CRN North West London Cardiovascular speciality lead and is actively involved in the development and recruitment for a number of multi-centre international clinical trials. Dr. Al-Lamee has over 60 peer-reviewed publications and has presented at international Cardiology conferences worldwide throughout her clinical career. She leads a research team at the National Heart and Lung Institute at Imperial College London investigating many aspects of cardiac care with a predominant focus on stable coronary artery disease.